LMR Partners’s CG Oncology CGON Stock Holding History

LMR Partners’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.8M	Buy	+123,900	New	+$8.1M	0.03%	465

Other funds holding CGON

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LMR Partners's CGON Position: Q2 2026 in Review

LMR Partners opened a new position in CG Oncology (CGON) in Q2 2026: 20,000 shares worth $1.42M. The stake represents 0.01% of the portfolio and ranks #981 among its holdings. This is a return to the name: LMR Partners previously reported a position in CGON as recently as Q4 2025.

LMR Partners first reported a position in CGON in Q1 2024 and has held it in 4 quarters since. 228 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

LMR Partners held 20,000 shares of CG Oncology worth $1.42M as of Q2 2026.
CG Oncology was a new LMR Partners position in Q2 2026.
CG Oncology made up 0.01% of LMR Partners's portfolio in Q2 2026, its #981 holding.
LMR Partners first reported a position in CG Oncology in Q1 2024 and has held it in 4 quarters since.
228 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.